Botox contains the deadly botulism toxin. When injected in small doses, the chemical paralyzes a muscle and prevents it from contracting, eliminating facial wrinkles. It has also been found to have other therapeutic uses.
It was first approved in the US 20 years ago for the treatment of eye muscle disorders.
The global settlement concludes a two-and-a-half year investigation that some analysts have said has held up FDA approval for treatment of migraines. Botox, already Allergan’s top product with $1.3 billion in annual sales, may generate an additional $1 billion with use in migraines, according to Aaron Gal, an analyst at Sanford C. Bernstein & Co. in New York.
“The resolution removes an overhang/concern for investors,” Larry Biegelsen, an analyst at Wells Fargo Securities in New York, said in a note to clients today. “The $600 million settlement amount appears reasonable based on industry standards.”
Source-Medindia